New Product for Cholesterol

[Guest guest]

Here is a News Release regarding a new product for lowering

cholesterol.

 

Greg Murphy

gamurphy64

 

 

NEWS RELEASE

 

FOR FURTHER INFORMATION, CONTACT:

 

David G. Kreher Fred Nielson Al Palombo

Chief Operating Officer Investor Relations Cameron Associates

(636) 537-9715 (636) 733-1314 (212) 554-5488

 

 

RELIV INTERNATIONAL ANNOUNCES RELEASE OF

CLINICAL STUDY RESULTS ON NEW PRODUCT

 

 

Study Shows Product Is Effective in Significantly Reducing

Elevated Total Blood Cholesterol Levels

 

 

CHESTERFIELD, MO, January 12, 2005 -- Relìv International, Inc.

(Nasdaq/NM - RELV), an international manufacturer and network

marketer of nutritional supplements and food products, announced the

release of results of an independent clinical trial on a dietary

supplement newly developed by Reliv scientists.

 

The clinical trial was conducted under the direction of Joe Vinson,

Ph.D., a Professor of Chemistry at the University of Scranton. Dr.

Vinson has over 25 years of research and clinical experience with

dietary supplements. The study sought to determine whether long-term

supplementation with the use of Reliv's new formulation would have an

influence on plasma lipids in subjects with elevated cholesterol

levels, in a double-blind, placebo crossover design.

 

The results of the trial showed statistically significant decreases

in participants' bad cholesterol (LDL) and triglyceride levels,

decreases in the cholesterol/good cholesterol (HDL) ratio and

decreases in the bad to good (LDL/HDL) ratios. Subjects participating

in the trial initially were identified as having undesirable

cholesterol ratios but, after a period of supplementation with the

Reliv formulation, had achieved desirable levels. In addition, the

trial results also showed improvement in cholesterol levels for those

participants who were already taking statin (cholesterol-reducing)

drugs.

 

The summary report on the clinical trial states that the overall

effect of the program for participants in the study was a significant

reduction in the 10-year risk of developing cardiovascular disease.

 

" Almost 700,000 people die annually in the United States from heart

disease, " reported Dr. Carl W. Hastings, Vice President for Research

and Development of Reliv, who participated in development of the

Reliv formulation. " Heart disease is the number one cause of death in

the United States and diagnosed heart disease occurs in 11% of non-

institutionalized adults. High blood cholesterol is a major risk

factor for coronary heart disease, " he said. " Our goal in developing

this new formulation has been to address the serious health risks

caused by elevated cholesterol levels in such a high proportion of

our population. "

 

" The clinical trial on this new formulation has established not only

its efficacy but also included testing which establishes the safety

of the formulation for use by the participants, " reported David

Barnes, Vice President Technical Affairs and Manufacturing

Operations.

 

Reliv plans to introduce the new product at its Phoenix Leadership

Conference on February 5, 2005.

 

Reliv distributes its products exclusively through its network of

independent distributors in the United States and 9 other countries.